Fiche publication
Date publication
novembre 2015
Journal
Cancer chemotherapy and pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
Tous les auteurs :
You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Hénin E, Guitton J, Tod M, Freyer G
Lien Pubmed
Résumé
Relationships between pharmacokinetic (PK) parameters of etoposide and toxicity survivals were reported in cancer patients treated at standard doses. The clinical impact of PK variations of etoposide high doses has never been explored in lymphoma patients.
Mots clés
Adult, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Bilirubin, blood, Carmustine, administration & dosage, Creatinine, blood, Cytarabine, administration & dosage, Disease-Free Survival, Etoposide, administration & dosage, Female, Hodgkin Disease, drug therapy, Humans, Kaplan-Meier Estimate, Lymphoma, Non-Hodgkin, drug therapy, Male, Melphalan, administration & dosage, Middle Aged, Peripheral Blood Stem Cell Transplantation, Prognosis, Proportional Hazards Models, Prospective Studies, Risk Assessment, Serum Albumin, analysis, Transplantation, Autologous, Treatment Outcome, Young Adult
Référence
Cancer Chemother. Pharmacol.. 2015 Nov;76(5):939-48
